Search results
Results from the WOW.Com Content Network
I, on the other hand, felt like I woke up one day with menopause in full swing and experienced a sudden onset of symptoms that included sleep disturbances, mood swings, fatigue, weight gain, joint ...
There is a non-statistically significant increased rate of breast cancer for hormone replacement therapy with synthetic progestogens. [6] The risk may be reduced with bioidentical progesterone, [61] though the only prospective study that suggested this was underpowered due to the rarity of breast cancer in the control population.
The effects of hormonal birth control on breast cancer risk have been studied for decades. Many studies over the years have shown that hormone-containing birth control options, specifically ...
The side effects of cyproterone acetate (CPA), a steroidal antiandrogen and progestin, including its frequent and rare side effects, have been studied and characterized.It is generally well-tolerated and has a mild side-effect profile, regardless of dosage, when it used as a progestin or antiandrogen in combination with an estrogen such as ethinylestradiol or estradiol valerate in women.
Initially, I was wary about using an estrogen product because my breast cancer was hormone sensitive, but he reaffirmed that the research regarding topical estrogen and breast cancer risk shows ...
[151] [153] In addition to breast cancer risk, estrogen alone and estrogen plus progestogen therapy are associated with higher breast cancer mortality. [154] With 20 years of use, breast cancer incidence is about 1.5-fold higher with estrogen alone and about 2.5-fold higher with estrogen plus progestogen therapy relative to non-use. [151]
Menopause brings with it many side effects that can be tricky to navigate. One that many women experience is weight gain. Typically, women in menopause gain about one pound a year, however, 20% of ...
Oral NOMAC was under development for the treatment of breast cancer and for use as a progestogen-only pill for birth control but did not complete development for these indications. [55] An estradiol and NOMAC vaginal ring was under development for use in birth control and to treat dysmenorrhea but did not complete development and was not ...